Publications by authors named "J D Rouillon"
Molybdenum disulfide (MoS) is a notable two-dimensional (2D) transition metal dichalcogenide (TMD) with properties ideal for nanoelectronic and optoelectronic applications. With growing interest in the material, it is critical to understand its layer-number-dependent properties and develop strategies for controlling them. Here, we demonstrate a photo-modulation of MoS flakes and elucidate layer-number-dependent charge transfer behaviors.
View Article and Find Full Text PDFArticle Synopsis
- Glycogen storage disease type III (GSDIII) is a rare condition caused by a deficiency in the glycogen debranching enzyme, leading to liver issues and muscle weakness, with no current cure available.
- Previous research indicated that using two dual AAV (adeno-associated virus) vectors to deliver the GDE gene could effectively target both liver and muscle in a GSDIII mouse model.
- This study investigated the combination of rapamycin and AAV gene therapy, finding that the treatment improved outcomes by reducing immune response and enhancing the therapeutic effect, supporting further clinical applications.
The ability to modulate optical and electrical properties of two-dimensional (2D) semiconductors has sparked considerable interest in transition metal dichalcogenides (TMDs). Herein, we introduce a facile strategy for modulating optoelectronic properties of monolayer MoSe with external light. Photochromic diarylethene (DAE) molecules formed a 2-nm-thick uniform layer on MoSe, switching between its closed- and open-form isomers under UV and visible irradiation, respectively.
View Article and Find Full Text PDFGlycogen storage disease type III (GSDIII) is a rare inborn error of metabolism affecting liver, skeletal muscle, and heart due to mutations of the AGL gene encoding for the glycogen debranching enzyme (GDE). No curative treatment exists for GSDIII. The 4.
View Article and Find Full Text PDFPurpose: The aim of this study was to evaluate the efficacy and safety of radiofrequency ablation (RFA) in the management of haemorrhoidal disease with 1 year's follow-up.
Method: This prospective multicentre study assessed RFA (Rafaelo) in outpatients with grade II-III haemorrhoids. RFA was performed in the operating room under locoregional or general anaesthesia.